Company News

Imugene (ASX:IMU) secures core US patent

02 Oct 2020 - Immuno-oncology company, Imugene (ASX:IMU) has been granted a patent from the US United States Patent and Trademark Office which it says protects its cancer growth factor immunotherapy platform.

Read more...